Support information

Dextranated Poly(Urethane Amine)s Designed for Systemic Gene Delivery in Ovarian Cancer Therapy

Jie Zhao, Fei Han, Peng Zhao, Xuejun Wen, Chao Lin*

The Institute for Translation Medicine, Shanghai East Hospital, The Institute for Biomedical Engineering and Nanoscience, Tongji University School of Medicine, Shanghai, 200092, P. R. China

*Corresponding author.

E-mail: chaolin@tongji.edu.cn (C. Lin)
Tel: +86-21-65983706-222. Fax: +86-21-65983706-0
Fig. S1. $^1$H NMR spectrum of dextran-PUA conjugate.

Fig. S2. $^1$H NMR spectrum of folate-modified dextran-PUA conjugate.
Fig.S3. Particle size and zeta potential of Dex-PUA or Dex-PUA-FA polyplexes. *P<0.05.

Fig.S4. Cytotoxicity analysis showing cell viability after SKOV-3 cells were co-incubated with the polyplexes of Dex-PUA polycations at different N/P ratios (5/1-20/1). The LPEI and BPEI were used as a control.
**Fig. S5.** a, c) Transfection activity in vitro of Dex-PUA based polyplexes in a) MCF-7 cells and c) Hela cells; b, d) Cytotoxicity in vitro of Dex-PUA based polyplexes in b) MCF-7 cells and d) Hela cells; e) cytotoxicity of Dex-PUA polycations against SKOV-3 cells as a function of polymer concentrations. BPEI at an N/P ratio of 10/1 is used as a control. *P<0.05, **P<0.01 and ***P<0.001.
Fig.S6. a) Fluorescence histogram of SKOV-3 cells treated by yoyo-1-labeled DNA containing polypelexes of Dex10k-PUA40 (red) and Dex10k-PUA40-FA (green). Untreated cells (black) were used as a blank control. The inserted is quantitative data on the percentage of yoyo-1 positive SKOV-3 cells, which shows that Dex10k-PUA40-FA can induce higher gene uptake into the cells as compared to Dex10k-PUA40; b) Free folate (50-200 μM) inhibits transfection efficiency of Dex10k-PUA40-FA against SKOV-3 cells. ***P<0.001, **P<0.01
Fig. S7. Cell viability 24 h after co-incubating SKOV-3 cells with Dex-PUA, Dex-PUA-FA polymers and 25kDa BPEI at different polymer concentrations.

Fig. S8. ELISA assay showing VEGF expression in SKOV-3 cells 24 h after transfection with Dex10k-PUA40-FA polyplexes containing shRNA-VEGF at different N/P rations. BPEI and LPEI polyplexes were used as a positive control. *P<0.05; NS: not significant
Fig. S9. Immunohistochemistry staining showing VEGF (up) and CD31 (down) expression in tumor tissue 11 days after shRNA-VEGF gene therapy using Dex10k-PUA40-FA.

Fig. S10. a) Mouse weight as a function of time within 11 days of shRNA-VEGF gene therapy; b) Routine blood assays showing typical biomarkers 11 days after the gene therapy using polymeric vectors or PBS as a blank control.